13F Holdings
中文EN

AQST Aquestive Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1398733 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.5%
TTM net income YoY-14.9%
TTM EPS YoY7.1%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—

Margins

Gross margin65.3%
Operating margin-114.1%
Net margin-162.3%
FCF margin-83.3%
EBITDA margin-113.0%

Returns

ROE—
ROA-56.0%
ROIC (approx.)—
Asset turnover0.35x

Leverage & solvency

Liabilities / assets159.4%
Debt / equity—
Current ratio6.12x
Interest coverage-5.39x

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue1.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$44.55M$57.56M$50.58M$47.68M$50.83M
Cost of revenue$18.55M$17.87M$20.83M$19.39M—
Gross profit$25.99M$39.69M$29.75M$28.29M—
R&D expense$17.19M$20.28M$13.10M$17.48M$17.05M
SG&A expense$79.85M$50.18M$31.75M$52.88M$53.48M
Operating income-$71.05M-$30.77M-$15.10M-$42.07M-$34.68M
Interest expense$11.12M$11.12M$6.34M$6.55M$10.05M
Pretax income-$83.78M-$44.15M-$7.62M-$54.41M-$70.54M
Income tax$0-$14,000$245,000$0$0
Net income-$83.78M-$44.14M-$7.87M-$54.41M-$70.54M
EBITDA-$70.50M-$30.05M-$13.76M-$39.68M-$31.71M
EPS (basic)-0.78-0.51-0.13-1.12-1.85
EPS (diluted)-0.78-0.51-0.13-1.12-1.85
Weighted avg. shares (diluted)106.93M86.73M61.26M48.73M38.08M
Balance sheet
Cash & equivalents$121.17M$71.55M$23.87M$27.27M$28.02M
Receivables$17.76M$7.34M$8.47M——
Inventory$6.17M$6.04M$6.77M$5.78M$4.04M
Current assets$149.27M$88.22M$40.97M$39.89M$47.26M
PP&E, net$3.89M$3.80M$4.18M$4.08M$5.05M
Intangibles$0$0$1.28M$1.44M$51,000
Total assets$160.43M$101.42M$57.42M$57.07M$61.99M
Current liabilities$47.61M$18.86M$18.31M$39.53M$21.96M
Short-term debt$9.99M————
Long-term debt$27.52M$32.50M$27.51M$33.45M—
Total debt$37.51M$32.50M$27.51M$33.45M—
Total liabilities$194.09M$161.58M$163.91M$175.62M$144.13M
Shareholders' equity-$33.66M-$60.16M-$106.49M-$118.55M-$82.13M
Net debt-$83.66M-$39.05M$3.64M$6.17M—
Shares outstanding122.04M91.41M68.53M54.83M41.23M
Cash flow statement
Operating cash flow-$52.43M-$35.76M-$6.38M-$9.82M-$32.98M
Capital expenditure$562,000$159,000$995,000$1.02M$913,000
Free cash flow-$52.99M-$35.92M-$7.38M-$10.84M-$33.89M
Investing cash flow-$562,000-$159,000-$995,000-$2.52M-$913,000
Financing cash flow$102.62M$83.59M$3.97M$11.59M$30.11M
Depreciation & amortization$548,000$718,000$1.34M$2.39M$2.96M
Stock-based compensation$7.62M$7.10M$2.69M$4.38M$6.82M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.